Circulating exosomal microRNAs as biomarkers of colon cancer. 2014

Hiroko Ogata-Kawata, and Masashi Izumiya, and Daisuke Kurioka, and Yoshitaka Honma, and Yasuhide Yamada, and Koh Furuta, and Toshiaki Gunji, and Hideki Ohta, and Hiroyuki Okamoto, and Hikaru Sonoda, and Masatoshi Watanabe, and Hitoshi Nakagama, and Jun Yokota, and Takashi Kohno, and Naoto Tsuchiya
Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.

OBJECTIVE Exosomal microRNAs (miRNAs) have been attracting major interest as potential diagnostic biomarkers of cancer. The aim of this study was to characterize the miRNA profiles of serum exosomes and to identify those that are altered in colorectal cancer (CRC). To evaluate their use as diagnostic biomarkers, the relationship between specific exosomal miRNA levels and pathological changes of patients, including disease stage and tumor resection, was examined. METHODS Microarray analyses of miRNAs in exosome-enriched fractions of serum samples from 88 primary CRC patients and 11 healthy controls were performed. The expression levels of miRNAs in the culture medium of five colon cancer cell lines were also compared with those in the culture medium of a normal colon-derived cell line. The expression profiles of miRNAs that were differentially expressed between CRC and control sample sets were verified using 29 paired samples from post-tumor resection patients. The sensitivities of selected miRNAs as biomarkers of CRC were evaluated and compared with those of known tumor markers (CA19-9 and CEA) using a receiver operating characteristic analysis. The expression levels of selected miRNAs were also validated by quantitative real-time RT-PCR analyses of an independent set of 13 CRC patients. RESULTS The serum exosomal levels of seven miRNAs (let-7a, miR-1229, miR-1246, miR-150, miR-21, miR-223, and miR-23a) were significantly higher in primary CRC patients, even those with early stage disease, than in healthy controls, and were significantly down-regulated after surgical resection of tumors. These miRNAs were also secreted at significantly higher levels by colon cancer cell lines than by a normal colon-derived cell line. The high sensitivities of the seven selected exosomal miRNAs were confirmed by a receiver operating characteristic analysis. CONCLUSIONS Exosomal miRNA signatures appear to mirror pathological changes of CRC patients and several miRNAs are promising biomarkers for non-invasive diagnosis of the disease.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic

Related Publications

Hiroko Ogata-Kawata, and Masashi Izumiya, and Daisuke Kurioka, and Yoshitaka Honma, and Yasuhide Yamada, and Koh Furuta, and Toshiaki Gunji, and Hideki Ohta, and Hiroyuki Okamoto, and Hikaru Sonoda, and Masatoshi Watanabe, and Hitoshi Nakagama, and Jun Yokota, and Takashi Kohno, and Naoto Tsuchiya
February 2017, Cancer gene therapy,
Hiroko Ogata-Kawata, and Masashi Izumiya, and Daisuke Kurioka, and Yoshitaka Honma, and Yasuhide Yamada, and Koh Furuta, and Toshiaki Gunji, and Hideki Ohta, and Hiroyuki Okamoto, and Hikaru Sonoda, and Masatoshi Watanabe, and Hitoshi Nakagama, and Jun Yokota, and Takashi Kohno, and Naoto Tsuchiya
January 2023, Frontiers in immunology,
Hiroko Ogata-Kawata, and Masashi Izumiya, and Daisuke Kurioka, and Yoshitaka Honma, and Yasuhide Yamada, and Koh Furuta, and Toshiaki Gunji, and Hideki Ohta, and Hiroyuki Okamoto, and Hikaru Sonoda, and Masatoshi Watanabe, and Hitoshi Nakagama, and Jun Yokota, and Takashi Kohno, and Naoto Tsuchiya
August 2020, Oncology letters,
Hiroko Ogata-Kawata, and Masashi Izumiya, and Daisuke Kurioka, and Yoshitaka Honma, and Yasuhide Yamada, and Koh Furuta, and Toshiaki Gunji, and Hideki Ohta, and Hiroyuki Okamoto, and Hikaru Sonoda, and Masatoshi Watanabe, and Hitoshi Nakagama, and Jun Yokota, and Takashi Kohno, and Naoto Tsuchiya
January 2020, Clinics (Sao Paulo, Brazil),
Hiroko Ogata-Kawata, and Masashi Izumiya, and Daisuke Kurioka, and Yoshitaka Honma, and Yasuhide Yamada, and Koh Furuta, and Toshiaki Gunji, and Hideki Ohta, and Hiroyuki Okamoto, and Hikaru Sonoda, and Masatoshi Watanabe, and Hitoshi Nakagama, and Jun Yokota, and Takashi Kohno, and Naoto Tsuchiya
January 2020, Disease markers,
Hiroko Ogata-Kawata, and Masashi Izumiya, and Daisuke Kurioka, and Yoshitaka Honma, and Yasuhide Yamada, and Koh Furuta, and Toshiaki Gunji, and Hideki Ohta, and Hiroyuki Okamoto, and Hikaru Sonoda, and Masatoshi Watanabe, and Hitoshi Nakagama, and Jun Yokota, and Takashi Kohno, and Naoto Tsuchiya
August 2018, Melanoma research,
Hiroko Ogata-Kawata, and Masashi Izumiya, and Daisuke Kurioka, and Yoshitaka Honma, and Yasuhide Yamada, and Koh Furuta, and Toshiaki Gunji, and Hideki Ohta, and Hiroyuki Okamoto, and Hikaru Sonoda, and Masatoshi Watanabe, and Hitoshi Nakagama, and Jun Yokota, and Takashi Kohno, and Naoto Tsuchiya
February 2017, Oncotarget,
Hiroko Ogata-Kawata, and Masashi Izumiya, and Daisuke Kurioka, and Yoshitaka Honma, and Yasuhide Yamada, and Koh Furuta, and Toshiaki Gunji, and Hideki Ohta, and Hiroyuki Okamoto, and Hikaru Sonoda, and Masatoshi Watanabe, and Hitoshi Nakagama, and Jun Yokota, and Takashi Kohno, and Naoto Tsuchiya
January 2017, Current pharmaceutical design,
Hiroko Ogata-Kawata, and Masashi Izumiya, and Daisuke Kurioka, and Yoshitaka Honma, and Yasuhide Yamada, and Koh Furuta, and Toshiaki Gunji, and Hideki Ohta, and Hiroyuki Okamoto, and Hikaru Sonoda, and Masatoshi Watanabe, and Hitoshi Nakagama, and Jun Yokota, and Takashi Kohno, and Naoto Tsuchiya
January 2022, Current oncology (Toronto, Ont.),
Hiroko Ogata-Kawata, and Masashi Izumiya, and Daisuke Kurioka, and Yoshitaka Honma, and Yasuhide Yamada, and Koh Furuta, and Toshiaki Gunji, and Hideki Ohta, and Hiroyuki Okamoto, and Hikaru Sonoda, and Masatoshi Watanabe, and Hitoshi Nakagama, and Jun Yokota, and Takashi Kohno, and Naoto Tsuchiya
October 2020, Clinical and translational medicine,
Copied contents to your clipboard!